Veracyte Announces Second Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Tech selloff weighs down Wall Street as bond yields climb
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Francisco Partners to acquire Weave Communications for $650M
Piper Jaffray Trims PT on Veracyte (VCYT) to $12, Maintains 'Overweight'
August 14, 2015 7:33 AM EDTPiper Jaffray analyst William Quirk reiterated an Overweight rating but trimmed his price target on Veracyte, Inc (NASDAQ: VCYT) to $12.00 (from $13.00) following Q3 results and outook.
Quirk commented, "Veracyte reported a 37.2% yoy revenue increase to $11.9M, above our $11.7M estimate, but below... More
Veracyte (VCYT) Misses Q2 EPS by 4c
August 13, 2015 4:35 PM EDTVeracyte (NASDAQ: VCYT) reported Q2 EPS of ($0.35), $0.04 worse than the analyst estimate of ($0.31). Revenue for the quarter came in at $11.9 million versus the consensus estimate of $12.23 million.
Veracyte reaffirmed FY2015 guidance.
"We continue to see strong growth of Afirma across both community-based physicians... More
